IKT
Inhibikase Therapeutics, Inc. · Healthcare · Market cap $231.6M
Insider Buying
$3.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Latest filing
Jul 31, 2026
Sands Capital Life Sciences Pulse Fund II, L.P.
Inhibikase Therapeutics, Inc. (IKT) has 6 SEC Form 4 filings (6 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jul 31, 2026.
Inside the rolling window, 1 insider at Inhibikase Therapeutics, Inc. reported 1 open-market purchase totaling $3.0M and no open-market sales. The most recent open-market filing is a purchase of 2,068,965 shares by 10% Owner Sands Capital Life Sciences Pulse Fund II, L.P., dated Nov 21, 2025, worth $3.0M.
- Industry:Biotechnology
- CEO:Mark T. Iwicki
- Employees:35
- HQ:Wilmington, DE, US
- IPO:2020-12-23
| Source | |||||||
|---|---|---|---|---|---|---|---|
Sands Capital Life Sciences Pulse Fund II, L.P.First filing | 10% Owner | Purchase | 2,068,965 | $3.0M | Nov 24 | +7.1% | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does IKT have?
Inhibikase Therapeutics, Inc. (IKT) has 6 SEC Form 4 filings (6 transaction rows) in the rolling 365-day window, disclosed by 1 distinct insider. Most recent filing: Jul 31, 2026.
When was the most recent SEC Form 4 filing for IKT?
The most recent Form 4 filing for IKT on Tracefour is dated Jul 31, 2026.
What is the total insider buy and sell value at IKT in the current window?
Inside the rolling window, insiders at IKT bought $3.0M and sold $0 based on SEC Form 4 filings.
Can I get alerts for IKT insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Inhibikase Therapeutics, Inc. (IKT). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Inhibikase Therapeutics, Inc. is in the Healthcare sector.